Varazdin buy marijuana

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

>>>✅(Click Here)✅<<<

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Varazdin buy marijuana

Previous page Next page. Menu Language.

SynBiotic — Platform primed for growth

Varazdin buy marijuana

Investment Companies. We will only use your personal information to provide the services and products that you have signed up for. You will receive a confirmation email after subscribing and can tailor your preferences or unsubscribe at any time by using the links provided. SynBiotic has built up a leading platform company that spans the hemp and cannabis industry to cover the full value chain, from cultivation through to sales. Management buys and builds ventures that create and market hemp, cannabis and cannabinoid products for both medical and recreational use, while continually seeking investments in exciting new verticals. Recreational cannabis use has recently been partially legalised in Germany, while the same legislative changes have benefited the medicinal market. Having built its platform prior to these changes, SynBiotic is seeing its investments bear fruit and we believe it is well-positioned for any further relaxation in cannabis legalisation in Germany. Market cap. Share price graph. Share details. Shares in issue. Last reported net debt as at 31 December Business description. SynBiotic is an investment holding company that pursues an EU-focused buy-and-build approach. The group of companies covers the entire supply chain, from cultivation to production to retail of hemp and cannabis products. One of the core businesses of the platform company is the research and development of new cannabinoid and terpene-based solutions for pain, sleep and anxiety. Its products serve a variety of end-markets including medicine and healthcare, nutrition and cosmetics. Large global market for cannabinoid products in multiple applications, with many legislators looking at relaxing rules, most recently Germany. Diversified businesses covering three sectors: industrial hemp, medical cannabis and recreational cannabis. Strong leadership team and portfolio managers. Execution risk in terms of integration and future investments. Potential competition from large players. Milo Bussell. Russell Pointon. Edison profile page. Historical financial figures. Year end. Source: SynBiotic. Management looks for companies that fit strategically, while also exploring growing verticals. It seeks to generate synergies between its investments, which is a competitive advantage relative to peers that tend to focus on a specific area of the market. Partial legalisation sparks up the German market. Recreational cannabis use has been partially legalised in Germany since 1 April , with adults allowed to possess 25g in public or 50g in private. Limited home cultivation is also legal. Furthermore, cannabis has been removed from the German Narcotics Act, enabling medical professionals to prescribe medicinal cannabis more easily to patients. Company description: A synergistic and diversified cannabis platform. SynBiotic was established to take advantage of the growing consumer acceptance of cannabinoids and industrial hemp across a range of applications, including healthcare pain, sleep and anxiety solutions , nutrition, cosmetics and animal food supplements. This should enable SynBiotic to operate more efficiently and to effectively navigate any legislative restrictions. Current laws in Germany allow producers to import cannabis for medicinal purposes, but not for recreational use. On 1 April , recreational cannabis was partially legalised in Germany, a significant step for SynBiotic and the broader European cannabis market. SynBiotic has sought to diversify its revenues in recent years through its investments, having previously been heavily reliant on the distribution segment. Cannabinoids, of which the two main ones are deltatetrahydrocannabinol THC and cannabidiol CBD , constitute more than natural active ingredients of the hemp plant cannabis sativa. These chemical compounds can have a positive medical or cosmetic effect by interacting with specific receptors within the central nervous system. By influencing how cells communicate, cannabinoids regulate numerous activities, including mood, sleep, memory and appetite. SynBiotic was known as Ledgertech until April when it was renamed in keeping with the realignment of its strategy. Significant events as SynBiotic has built up its platform include:. In March , SynBiotic announced a further acquisition and another capital increase: it acquired a In April , SynBiotic announced an in-kind capital increase for the takeover of Lean Labs and the remaining share of Solidmind Group. In November , SynBiotic acquired This group of companies belonged to hemp and cannabis industry pioneer Daniel Kruse and the takeover was again funded by a capital increase. Further capital increases were announced in September and October , with the stated objective of further expanding the existing business and continuing to pursue the buy-and-build strategy. Most recently, SynBiotic expanded its medicinal cannabis capabilities through the acquisition of WEECO Pharma, a German importer and wholesale platform that connects medicinal cannabis producers. Company Name. Date of acquisition. Lean Labs Pharma. Hemp Factory. Hempro International. MH medical hemp. SynBiotic Distribution. Canna Abgabestellen Franchise. Ilesol Pharmaceuticals. Exhibit 2: SynBiotic segments and company portfolio. SynBiotic is looking to become a leading platform in the cannabinoids industry through targeted acquisitions of companies that together span the value chain of the industrial hemp and cannabis sectors. Below we outline the group structure across its segments. The aim is to build a strong European group of companies with experienced and promising businesses in order to cover the relevant growth markets and at the same time minimise risks for investors through diversification. Cultivation: SynBiotic has invested in companies that cultivate and grow cannabis and hemp, to cover the full value chain of the cannabis plant:. Hanf Farm It produces raw materials such as organic hemp seed and leaves and hemp oil, among others. It also provides agricultural services for hemp such as harvesting, drying, cleaning and processing. Hemp Factory In addition to the germ reduction, cleaning, hulling and roasting of hemp seeds, the range of services includes the production of hemp oil, hemp flour, hemp protein powder and hemp fibre. Customers include food and baked goods manufacturers. The company also produces animal feed. Sales and distribution: SynBiotic buys and builds strong medical and DTC brands to enhance distribution to customers. Within this segment, SynBiotic is focused on the medicinal cannabis market, due to it being a more regulated and fast growing segment. Other rapidly evolving areas, including hemp and recreational cannabis, are monitored so SynBiotic can capitalise as and when required. After extraction through a CO 2 process, Hempamed oils are gently filtered to keep as close to the original plant structure as possible. Hempro International MH medical hemp It produces and sells medicinal and pharmaceutical cannabis products. Management is refocusing the business by closing some of the smaller stores in Austria and growing the online platform. The group is considering opening retail stores in Germany. Bushdoctor offers cannabis accessories and products across the spectrum, from seeds and hemp plants to CBD products and smoking accessories. The company is a platform that connects cannabis EU-GMP approved producers through its position as an importer and wholesaler in medicinal cannabis. Despite cannabis being used for various medical purposes for thousands of years and having a safety profile that is superior to alcohol in many respects , there are surprisingly few therapeutics containing cannabis that have been approved by major regulatory authorities. Within Germany, the use of medical cannabis has been legal since following the passing of the Medicinal Cannabis Act. Regulation in made the process of obtaining a prescription for medicinal cannabis more accessible for patients and health insurance providers, for which the guidance has been clarified. Germany is now one of the only countries where medical cannabis treatment is covered under a public health insurance system. This classification had generally discouraged cannabis use for medical purposes. Although governments retain jurisdiction over the classification of cannabis, the decision signalled the intent to loosen international controls. While the use of recreational cannabis is illegal in most countries, the German government passed partial legalisation in February permitting regional pilot projects that allow for the production and sale of cannabis in designated areas. There were votes in favour, rejections and four abstentions. Under the new law, from 1 April overs can possess 25g of cannabis in public and 50g in private, and up to three cannabis plants can be grown per person. However, the use of cannabis is restricted in designated public places, such as within sight of schools, sports centres and pedestrian zones, between 7am and 8pm. From 1 July , designated cannabis clubs can be formed with up to members, who are allowed to grow cannabis and distribute it to their members on a not-for-profit basis. The clubs are limited to dispense a maximum of 50g of cannabis per person per month. Members of the clubs must be residents of Germany membership is not available to tourists and membership is heavily regulated. While these changes represent a significant shift in legislature, the legalisation of commercial supply of cannabis is yet to be decided. Currently, as the recreational cannabis market is not-for-profit, supply can only come from home cultivation or through the cannabis clubs. The outcome of the regional trials may influence broader cannabis policies within Germany, which may pave the way for legalisation and guidance on the supply of recreational cannabis. In the US, the largest market for cannabis use, laws on recreational use are being relaxed. Already, 24 states and the District of Columbia have legalised the use of recreational cannabis, while 38 states have legalised the use of cannabis for medicinal purposes. In May , the US Department of Justice reclassified cannabis from a Schedule I controlled substance, a classification that includes addictive drugs such as heroin, to Schedule III, which classes it as a moderate or low-risk dependency drug. The move not only signals a change in attitudes towards recreational use, but could potentially enable greater clinical research and opportunities for pharmaceutical companies to submit new drug applications with cannabis-based products. Although SynBiotic does not operate in the US, it is nonetheless a key global market for cannabis and hemp products and could facilitate regulatory change in other markets. Key current and prospective market applications for SynBiotic. The hemp and cannabis market can be divided into three distinct segments: medical cannabis, recreational cannabis currently illegal in most jurisdictions and industrial hemp. SynBiotic believes it is well-positioned in all three of these markets, with products illustrated in Exhibit 3. Exhibit 3: SynBiotic products. Medical cannabis refers to herbal or plant-derived cannabis products that are prescribed by a medical professional. Products are available as herbal materials, oils, tinctures, food or capsules, and SynBiotic is working to expand this list. After epilepsy, pain is probably the area with the highest quantity of evidence associated with the efficacy of cannabinoids, and is a large market. Research into the benefits of CBD products for the treatment of chronic pain is, however, relatively mixed. Other substantial markets are sleep disorders and anxiety. The CDC estimates that between 50 million and 70 million people in the US suffer from chronic or ongoing sleep disorders, while the World Health Organization estimates nearly million people suffer from anxiety. The legalisation of medical cannabis is advanced across Europe with medical professionals being able to offer cannabis-containing medicines to patients with a serious illness since Doctors still tend to prescribe cannabis only when other therapies are ineffective, as very few cannabis products have been approved for pain; however, acceptance of medicinal cannabis is increasing steadily. Germany, however, has been relatively progressive in this field, with an estimated k active medical cannabis patients in April Following the partial legalisation in April, medicinal cannabis has been removed from the German Narcotics Act, resulting in less red tape to facilitate more prescriptions of medicinal cannabis. The recent changes to legislation could also boost domestic German medicinal cannabis production. SynBiotic is poised to take advantage of the changes in the regulation of recreational cannabis in Germany, having successfully built out a portfolio of companies that operate within the recreational cannabis value chain. The legalisation of the commercial sale of cannabis is likely to be a slower process compared to the pilot projects that have been put in place, particularly as cities and regions decide whether they would like to participate in the pilots. Although non-profit cannabis clubs are legal nationwide, owing to bureaucracy, many clubs have reported delays in obtaining licences and have found it difficult to comply with the current regulations. There are other legal considerations at both the state and broader EU level that may slow the process to full legalisation of the sale of recreational cannabis. Consequently, SynBiotic has sought to diversify its strategy to cover the wider CBD space with industrial hemp. Industrial hemp has a broad range of uses, including wellness and food, cosmetics, food supplements, animal foods, textiles and plastics among the many categories for finished products. We profile a few of these industries below to show the potential opportunities for SynBiotic. Many European countries do not allow the sale of CBD-containing food, citing insufficient data on the effects of CBD products on the body. Within Germany, applications for the approval of CBD-containing products are ongoing, however SynBiotic expects a favourable decision to be made by mid SynBiotic is active in the CBD-based dietary supplements market, which has grown steadily in recent years. Although this clearly is limited in comparison with the broader CBD market, it represents a rapidly growing segment of the market. Another use case is for hemp protein in industrial animal feed, which would represent a significant market opportunity for SynBiotic. At present there are regulatory concerns regarding the transfer of THC from animals to humans. However, benefits seen in trials relating to animal health, meat quality and lower methane production may encourage regulatory change. There remains a lack of participation within the cannabis market from the large biotechnology and pharmaceutical companies due to the complex intellectual property landscape. Although the clinical trial process for developing an FDA-approved cannabinoid product is no shorter than usual, the exclusivity can be short if the product is a reformulation of THC or CBD. In the US, Hatch-Waxman exclusivity for a product that is not a new chemical entity is only three years, compared to five for a new chemical entity. Patents in this area tend to be particularly narrow owing to the high level of prior art affecting the patentability of THC and CBD formulations. Any granted patents will likely be challenged once exclusivity expires. Within Europe there are very few cannabis competitors, with many companies focusing on a specific vertical such as medicinal cannabis or retail. SynBiotic believes it has a competitive edge due to its vertically integrated approach, which spans cultivation of cannabis through to production and distribution, bringing advantageous synergies. Direct competitors tend to be smaller-scale, privately owned companies. Management, organisation and corporate governance. German corporation law requires all public companies to have two boards: a management board and a supervisory board. The supervisory board oversees and appoints the members of the management board and must approve major business decisions. This independent, non-executive panel has the duty to hold management accountable and protect the interests of shareholders. In November , SynBiotic announced the creation of an advisory board, having secured Bruce Linton as its chairman. Linton is the founder and former chairman and CEO of Canopy Growth Corporation, and is one of the most experienced and most successful cannabis entrepreneurs and investors globally. The other member of the advisory board is Dr Thomas Haffner, who has over 25 years of experience in the pharmaceutical industry, with expertise in the conception and marketing of OTC drugs. We profile the key members of the executive team, management board and supervisory board:. He has been a board member of the European Industrial Hemp Association since and was elected its president in He also serves as the vice-chairman of the Federation of International Hemp Organisations. Rainer Seiler member of the supervisory board is a healthcare market consultant and entrepreneur with 20 years of leadership experience in a number of sectors including pharmaceuticals, e-commerce and wholesale. Frank Otto sits on the supervisory board. He has co-founded a number of companies in the healthcare market. The financial figures for FY23 showed a significant decline in revenues, largely reflecting the weaker consumer environment in Europe following the war in Ukraine and subsequent squeeze on household budgets. Period to 31 December. Cash flow from operations. Cash flow from investing. Cash flow from financing. Cash and cash equivalents at start of the year. Cash and cash equivalents at end of the year. The company will also likely continue its strategy of acquiring businesses through the issuance of additional shares, which may further dilute existing shareholders. Share price. FY24e revenue. Aurora Cannabis. Cronos Group. Canopy Growth Corp. Leafly Holdings. Tilray Brands. Peer group average. SynBiotic SE. SNDL has also seen a positive return of There is a risk that regulatory requirements will not be met. Apart from a current strict framework, the constant change in the regulatory environment for CBD and the sometimes unclear boundaries between pharmaceutical products, food and prohibited narcotics can make compliance difficult. If SynBiotic products are classified as medicinal products, they are subject to pharmaceutical approval and distribution rules. The approval process can be lengthy and varies from country to country. In addition, the legal framework for narcotics must be observed. For example, a tightening of the UK Medicines Act or of EU legislation around narcotics drugs, or its interpretation by courts, could be highly detrimental to sales of SynBiotic products, as could a tightening of the criminal code ie driving a motor vehicle under the influence of narcotics. Similarly, the legalisation process in Germany is subject to political agreement and there is a risk the process could be affected by political interference. In Germany, the partial legalisation of cannabis is being run through pilot trials, which does not guarantee full legalisation. Furthermore, administrators within more conservative states in Germany, including Bavaria, have already said they will reject notions to legalise cannabis at the national level. There is execution risk in terms of expansion, which is at the heart of the SynBiotic investment case. Planned growth is dependent on the availability of and access to profitable investments at attractive prices. The integration and management of acquisitions may not be successful. Shares may be issued for acquisitions, thereby diluting existing shareholders. The German market is exposed to intense global competition, which are able to produce cannabis at a lower cost. Consequently, the German cannabis market is, and will remain for the foreseeable future, an import market. Because of its international activities, SynBiotic is affected by economic risks in numerous countries. We note, however, that management undertook cost-cutting in FY23 in response to weaker trading, reducing the headcount from in FY22 to While the proceeds from capital increases are intended to be used to expand the investment portfolios, there is always the risk of overpaying for acquisitions. General disclaimer and copyright. This report has been commissioned by SynBiotic and prepared and issued by Edison, in consideration of a fee payable by SynBiotic. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services. Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note. No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors. Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest. This research is issued in Australia by Edison AU and any access to it, is intended only for 'wholesale clients' within the meaning of the Corporations Act of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument. New Zealand. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing including refraining from acquiring or disposing of securities. As such, it should not be relied upon in making an investment decision. United Kingdom. This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. This Communication is being distributed in the United Kingdom and is directed only at i persons having professional experience in matters relating to investments, i. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document. This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person. United States. Edison relies upon the 'publishers' exclusion' from the definition of investment adviser under Section a 11 of the Investment Advisers Act of and corresponding state securities laws. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Investment Companies Flash note. Financials Update. Industrials Update. TMT Update. Research: Consumer. Intralot reported better year-on-year growth in revenue and EBITDA in Q than Q, although foreign currency headwinds — notably from Argentina and Turkey — continued to dampen reported growth rates. Post period end, Intralot signed three-year contract extensions in the Netherlands and Ireland, highlighting the strength of its offering. In addition to retaining clients, the company is proactive in attempting to win a number of new contracts in North America and Australia. This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information. These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds. Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant. Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users. Main menu. Edison Group. Your Previous Searches:. Recently Visited Pages:. Equities by Sector. NioCorp Developments. MCap USD77m. Last close USD1. Newron Pharmaceuticals. MCap CHFm. Last close CHF8. Northern Data Group. MCap EUR1,m. Last close EUR Thematics View All Thematics. Audiovisual View All Audiovisual. About Edison. SynBiotic — Platform primed for growth. Market capitalisation EUR28m. More on this equity Meet this company. Meet this company. If you'd like to arrange a meeting with SynBiotic please complete this form. Please enable JavaScript in your browser to complete this form. Confirm Email. Ask the analyst. Follow this company. Research: Consumer 16 September Platform primed for growth. Leading the European cannabis industry. Valuation: Clear guidance laid out. Market overview. Medical cannabis. Recreational cannabis. Industrial hemp. Wellness and food. Food supplements. Animal food supplements. General disclaimer and copyright This report has been commissioned by SynBiotic and prepared and issued by Edison, in consideration of a fee payable by SynBiotic. United Kingdom This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. United States Edison relies upon the 'publishers' exclusion' from the definition of investment adviser under Section a 11 of the Investment Advisers Act of and corresponding state securities laws. Investment Companies Flash note Financials Update Industrials Update TMT Update More on SynBiotic View All. Latest from the Consumer sector View All Consumer content. Share this link via Or copy link. Subscribe to Edison Get access to the very latest content matched to your personal investment style. Sign up for free. Cookie Policy Overview. Strictly necessary and functional These cookies are used to deliver our website and content. Enable or Disable Cookies. Advertising Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. Please enable Strictly Necessary Cookies first so that we can save your preferences! Performance Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. Historical financial figures Year end.

Varazdin buy marijuana